Our results indicated that rMSC treatment dramatically reduced the fasting insulin level in serum and the compensatory hyperplasia in islets, accompanied by decreased mRNA expression of inflammation factors in liver (Figure S2), convincing that rMSCs therapeutically ameliorated liver steatosis and IR, and also had benefit to prevent the development of NASH. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.